Clinical Study to Evaluate the Efficacy and Safety of Desoximetasone (DSXS) With Atopic Dermatitis

• Status: Completed
• Trial end date: 2017-08-29
• Target enrollment: 0
• Participant gender: All

Summary

Efficacy and Safety of DSXS (Taro Pharmaceuticals, U.S.A., Inc.) in Patients with Moderate to Severe Atopic Dermatitis

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Taro Pharmaceuticals USA

Criteria

Inclusion Criteria:

• male and non-pregnant females, age 6 months or older, with a confirmed diagnosis of moderate to severe atopic dermatitis (AD)

Exclusion Criteria:

• Lacks stable diagnosis of atopic dermatitis or has been diagnosed with mild atopic dermatitis.